Marimed (MRMD) Depreciation & Amortization (CF) (2016 - 2026)

Marimed (MRMD) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $2.2 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.2 million, up 19.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.5 million (up 8.69% YoY), and the FY2025 annual result was $8.1 million, up 2.52% from the prior year.
• Depreciation & Amortization (CF) climbed to $2.2 million in Q1 2026 per MRMD's latest filing, from $2.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.2 million in Q4 2024 and troughed at $702000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.8 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 96.55% in 2024, then retreated 6.76% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $963000.0 in 2022, then soared by 77.67% to $1.7 million in 2023, then increased by 26.3% to $2.2 million in 2024, then slipped by 4.07% to $2.1 million in 2025, then increased by 3.86% to $2.2 million in 2026.
• Business Quant data shows MRMD's Depreciation & Amortization (CF) at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $2.1 million in Q3 2025.